TNF and psoriasis vulgaris: In adults with plaque psoriasis and psoriatic arthritis, a systematic review and meta-analysis of randomized, placebo-controlled studies of the TNF blockers etanercept, infliximab, adalimumab, golimumab, and certolizumab suggested no statistically significant evidence of an increased risk of cancer with these treatments.